Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Direct Regulation of Alternative Splicing by SMAD3 Through PCBP1 is Essential to the Tumor-Promoting Role of TGF-β

TGF-β1 Promotes Epithelial-to-mesenchymal Transition and Stemness of Prostate Cancer Cells by Inducing PCBP1 Degradation and Alternative Splicing of CD44

MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells.

Alternative splicing in EMT and TGF-β signaling during cancer progression

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

TGF- signaling regulates <i>SPOP</i> expression and promotes prostate cancer cell stemness

Transcriptional regulators ensuring specific gene expression and decision making at high TGFβ doses

Transcriptional regulators ensuring specific gene expression and decision-making at high TGF{beta} doses

Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers

Posttranslational Regulation of Smads

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

14-3-3ζ turns TGF-β to the dark side.

CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-β Signaling

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform

Opposing Roles of TGFβ and BMP Signaling in Prostate Cancer Development

TGF-β-induced MIR99AHG synergizes with PTBP1 to trigger a splicing switch of SMARCA1 that promotes invadopodia formation for metastasis in colorectal cancer

14-3-3 Zeta Turns Tgf-Beta to the Dark Side

Alternative splicing regulation by tumor suppressing subtransferable candidate 4: a pathway to tumor suppression

Novel Alternatively Spliced Variants of Smad4 Expressed in TGF-β-Induced EMT Regulating Proliferation and Migration of A549 Cells.